Hannover Re US Names Kelly Rabin Senior VP and Chief Actuary

Hannover Life Reassurance Company of America (Hannover Re US) announced that Kelly Rabin will assume the role of Senior Vice President and Chief Actuary effective May 1, 2026. The company described the appointment as a leadership step to oversee its actuarial, valuation and regulatory reporting activities.

According to the release, Rabin will lead a broad range of actuarial functions including regulatory reporting, financial reporting and valuation (FRV), financial planning and actuarial modelling. The move follows John Di Meo’s promotion to Executive Vice President and Chief Financial Officer on January 1, 2026; Di Meo previously served as Chief Actuary and Appointed Actuary for the company. Company directory information also lists Rabin among the firm’s senior actuarial staff prior to this appointment.

While personnel changes of this type typically do not trigger immediate market reactions, a chief actuary’s role is central to reserve adequacy, capital modelling and financial valuation in the life and health reinsurance sector. Strengthening actuarial leadership can support consistent FRV practices and regulatory compliance, particularly during periods of balance-sheet review or model updates. The company framed the appointment as ensuring continuity in these core functions.

The appointment should be viewed in the context of a broader leadership transition announced by Hannover Re US, which included senior executive changes and the retirement of long-serving leaders. That earlier restructuring, announced in late 2025, set the stage for subsequent role changes across finance, risk and actuarial functions. Observers see these coordinated moves as part of the firm’s governance and succession planning.

Hannover Re US stated that Rabin’s assuming of the chief actuary role is effective May 1, 2026, and that her remit will include maintaining regulatory reporting standards and overseeing valuation processes. Further operational and reporting details are expected to be disclosed in the company’s routine communications; for now the announcement clarifies the effective dates and immediate reporting lines. Market stakeholders will monitor ensuing FRV outputs and regulatory filings for any material shifts in assumptions or capital requirements.